Epigenetic cancer therapy: rationales, targets and drugs.
- Published in:
- Oncogene, 2012, v. 31, n. 39, p. 4257, doi. 10.1038/onc.2011.601
- By:
- Publication type:
- Article
Works matching IS 09509232 AND DT 2012 AND VI 31 AND IP 39
Results: 7
1
2
The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
- Published in:
- Oncogene, 2012, v. 31, n. 39, p. 4279, doi. 10.1038/onc.2011.595
- By:
- Publication type:
- Article
3
RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells.
- Published in:
- Oncogene, 2012, v. 31, n. 39, p. 4302, doi. 10.1038/onc.2011.596
- By:
- Publication type:
- Article
4
Functional interplay between p53 acetylation and H1.2 phosphorylation in p53-regulated transcription.
- Published in:
- Oncogene, 2012, v. 31, n. 39, p. 4290, doi. 10.1038/onc.2011.605
- By:
- Publication type:
- Article
5
Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish.
- Published in:
- Oncogene, 2012, v. 31, n. 39, p. 4333, doi. 10.1038/onc.2011.594
- By:
- Publication type:
- Article
6
Inhibition of cell migration by PITENINs: the role of ARF6.
- Published in:
- Oncogene, 2012, v. 31, n. 39, p. 4317, doi. 10.1038/onc.2011.593
- By:
- Publication type:
- Article
7
CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
- Published in:
- Oncogene, 2012, v. 31, n. 39, p. 4266, doi. 10.1038/onc.2011.599
- By:
- Publication type:
- Article